Systemic Adverse Effects Associated with Topically Applied Latanoprost

Mishima HK Masuda K Kitazawa Y Azuma I Araie M . A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week open study. Arch Ophthalmol 1996;114:929–32.

Kjellgren D Douglas G Mikelberg FS Drance SM Alm A . The short-term effect of latanoprost on the intraocular pressure in normal pressure glaucoma. Acta Opthalmol Scand 1995;73:233–6.

Rulo AH Greve EL Hoyng PF . Additive effect of latanoprost, a prostaglandin F₂ alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994;78:899–902.

Zaia N Dolan JW Kacere RD Brubaker RF . The effects on aqueous dynamics of PhXA41, a new prostaglandin F₂ alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111:1351–8.

Package insert. Xalatan (latanoprost). Woodstock, IL: Pharmacia & Upjohn, June 3, 1996.

McIntyre RC Agrafojo J Banerjee A Fullerton DA . Pulmonary vascular smooth muscle contraction. J Surg Res 1996;61:170–4.

Troug WE Norbeg M Thibeault DW . Effects of 8-epi-prostaglandin F(2alpha) and U46,619 on pulmonary hemodynamics in piglets. Biol Neonate 1997;71:306–16.

Okazawa A Kawikova I Cui ZH Skoogh BE Lotvall J . 8-epi-PGF(2al-pha) induces airflow obstruction and airway plasma exudation in vivo. Am J Respir Crit Care Med 1997;155:436–41.

Johnstone MA . Hypertrichosis and increased pigmentation of adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124:544–7.

James S . Center for Drug Evaluation and Research: Xalatan adverse drug reaction information. File Number F97–15017. Rockville, MD: Food and Drug Administration, 1997.

Rang HP Dale MM . Pharmacology. London: Churchill Livingstone, 1987.

Sodeman WA Sodeman TM . Pathologic physiology: mechanisms of disease. Philadelphia: WB Saunders Co., 1985.

Quilley J Bell-Quilley CP McGiff JC . Eicosanoids and hypertension. In: Laragh JH Brenner BM , eds. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press, Ltd., 1995.

Olin BR , ed. Facts and comparisons. St. Louis: Facts and Comparisons, 1997:118j.

Kappus H Diplock AT . Tolerance and safety of vitamin E: A toxicological position report. Free Radic Biol Med 1992;13:55–74.

Omaye ST . Safety of megavitamin therapy. Adv Exp Med Biol 1984;177:169–203.

Roberts HJ . Prospective of vitamin E as therapy. JAMA 1981;246:129–31.

Roberts HJ . Does vitamin E precipitate angina (letter)? Chest 1994;106:1636–7.

Roberts HJ . Thrombophlebitis associated with vitamin E therapy with a commentary on other medical side effects. Angiology 1979;30:167–76.